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Abstract
Background: Cervical cancer claims 311,000 lives annually, and 90% of these deaths occur in low- and middle-
income countries. Cervical cancer is a highly preventable and treatable disease, if detected through screening at an
early stage. Governments have a responsibility to screen women for precancerous cervical lesions. Yet, national
screening programmes overlook many poor women and those marginalised in society. Under-screened women
(called hard-to-reach) experience a higher incidence of cervical cancer and elevated mortality rates compared to
regularly-screened women. Such inequalities deprive hard-to-reach women of the full enjoyment of their right to
sexual and reproductive health, as laid out in Article 12 of the International Covenant on Economic, Social and
Cultural Rights and General Comment No. 22.
Discussion: This article argues first for tailored and innovative national cervical cancer screening programmes
(NCSP) grounded in human rights law, to close the disparity between women who are afforded screening and
those who are not. Second, acknowledging socioeconomic disparities requires governments to adopt and refine
universal cancer control through NCSPs aligned with human rights duties, including to reach all eligible women.
Commonly reported- and chronically under-addressed- screening disparities relate to the availability of sufficient
health facilities and human resources (example from Kenya), the physical accessibility of health services for rural and
remote populations (example from Brazil), and the accessibility of information sensitive to cultural, ethnic, and
linguistic barriers (example from Ecuador). Third, governments can adopt new technologies to overcome individual
and structural barriers to cervical cancer screening. National cervical cancer screening programmes should tailor
screening methods to under-screened women, bearing in mind that eliminating systemic discrimination may
require committing greater resources to traditionally neglected groups.
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Conclusion: Governments have human rights obligations to refocus screening policies and programmes on
women who are disproportionately affected by discrimination that impairs their full enjoyment of the right to
sexual and reproductive health. National cervical cancer screening programmes that keep the right to health
principles (above) central will be able to expand screening among low-income, isolated and other marginalised
populations, but also women in general, who, for a variety of reasons, do not visit healthcare providers for regular
screenings.
Keywords: Cervical cancer, Human papillomavirus, Sexual and reproductive health, Right to health, Human rights,
Cancer screening, Cancer prevention, National cancer policy, HPV test
Background
Cervical cancer is the fourth most common cancer in
women, globally. Every two minutes a woman dies of
cervical cancer around the world, resulting in 311,000
deaths annually [1]. Nine out of ten of these deaths
occur in low- and middle-income countries (LMICs)- a
fact that the World Health Organization (WHO)
Director-General Dr. Tedros Adhanom Ghebreyesus la-
bels ‘neither fair nor just’ [2]. Why? Cervical cancer is a
highly preventable and treatable disease if detected at an
early stage. Prevention and early detection is possible by
checking for abnormalities in the cells of the cervix. Also
the presence of the human papillomavirus (HPV) is an
indication that one might be at risk for cervical cancer;
especially the so called high-risk HPV types increase the
risk of malignant lesions. Two of them, HPV 16 and 18,
are found in over 70% of cervical cancer cases. These
preventative measures have long hinged on a functioning
health system, complete with trained gynaecologists, la-
boratory infrastructure, and vaccination and screening
programs. All of these measures are necessary to work
towards cervical cancer elimination, a global commit-
ment in the 2013–2020 Global Action Plan for the Pre-
vention and Control of Noncommunicable Diseases. The
UN Population Fund has promised to support national
health ministries in integrating this into existing repro-
ductive health programmes [3].
Governments have a three-part responsibility in rela-
tion to cervical cancer over the course of a woman’s life:
during her youth, to vaccinate against HPV; in midlife to
screen for precancerous cervical lesions; and at all ages
to treat cancer, if needed [4]. These times are crucial
thresholds that can become a life saved or a life lost. Of
these three moments, regular screening and follow-up of
all at-risk women is the pinnacle of cervical cancer con-
trol. When under-screened, women experience a higher
incidence of cervical cancer and elevated mortality rates
compared to regularly-screened women [5]. Yet, crucial
shortcomings in national cervical cancer screening pro-
grammes (NCSPs) mean they overlook many poor
women and those marginalised in society by their age,
ethnicity, disability, language, place of residence, and/or
recent immigration status, among other factors [6]. Such
inequalities harm women twice, first by making them
more vulnerable to acquiring HPV infections, and again
by depriving them of potentially lifesaving screening and
early cancer detection. Ultimately, these women cannot
enjoy their right to health, as laid out in Article 12 of
the International Covenant on Economic, Social and
Cultural Rights (ICESCR). The 2016 General Comment
No. 22 is an authoritative explanation of governments’
obligations to realise the right to sexual and reproductive
health (SRH) from Article 12 of the ICESCR.
At the core of this debate, is how NCSPs, especially
those in LMICs, can effectively reach populations vul-
nerable to HPV infections through policy and practice.
This article argues for tailored and innovative NCSPs
grounded in human rights law to close the disparity be-
tween women who are afforded screening and those
who are not. Human rights law has the potential to re-
orient social norms, political discourse, and govern-
ment’s legal obligations towards the needs of under-
served women and girls [7]. Some NCSPs may be framed
around human rights law, such as the Kenyan National
Cancer Control Strategy 2017–2022 mentioned below.
However, to the authors’ knowledge, no systematic study
of NCSPs’ alignment with human rights law has been
undertaken. Human rights-based screening programmes
have the potential to make an important contribution to
attaining, by 2030, a one-third reduction in premature
mortality from non-communicable diseases (NCDs),
such as cervical cancer (Sustainable Development Goal
Target 3.4).
In the following sections of this paper, we first exam-
ine States’ human rights obligations towards cervical
cancer control, including through NCSPs, as outlined in
General Comment No. 22, and the need to address dis-
parities. We then recommend that acknowledging socio-
economic disparities requires governments to adopt and
refine universal cancer control through NCSPs aligned
with human rights duties, including to reach all eligible
women. Third, we advocate for governments in coun-
tries with disparities in cervical cancer incidence and
mortality to adopt new technologies to overcome
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individual and structural barriers to cervical cancer
screening.
Discussion
Cervical cancer control as part of the right to sexual and
reproductive health
The right to the highest attainable standard of physical
and mental health (‘right to health’) is embedded in nu-
merous international treaties, including the most promin-
ent, the ICESCR. In total, 169 national governments (or
States) have ratified the ICESCR, and are therefore, legally
obliged to realise the right to health. Due to ongoing and
grave violations of people’s SRH, the UN Committee on
Economic, Social and Cultural Rights (UN CESCR) drew
attention to the ‘right to sexual and reproductive health’
(‘right to SRH’), a component of the right to health, in
General Comment No. 22 (2016) [4]. This is a non-
binding, yet highly authoritative, explanation of govern-
ment obligations to realise the right to SRH.
Each State must use its own means and methods to
realise the right to SRH with a maximum of its available
resources, according to General Comment No. 22. This
flexibility recognises that there is no ‘one-size-fits-all’ ap-
proach to SRH; instead, each government should use a
tailored strategy to respond to local SRH needs and
challenges within its own resources. Despite this flexibil-
ity, each State is under the immediate obligation “to
eliminate discrimination against individuals and groups
and to guarantee their equal right to SRH,” (4, para 34).
In other words, States must immediately ensure that
whatever their actions, they ensure equality and non-
discrimination for all, and even “implement temporary
special measures to overcome long-standing discrimin-
ation... and to eradicate conditions that perpetuate dis-
crimination,” (4, para 36), where needed. Notably, the
UN CESCR makes these legal obligations specific to re-
productive cancers in the provision (emphasis added):
States should aim to ensure universal access without
discrimination for all individuals, including those
from disadvantaged and marginalised groups, to a
full range of quality SRH care, including... [the] pre-
vention, diagnosis, and treatment of ... reproductive
cancers... (4, para 45).
States also have ‘core obligations’ under the right to SRH,
which signify the basic minimum level that governments
must achieve in order to give meaning to the right to
SRH. Among these core obligations is the duty to “guaran-
tee universal and equitable access to affordable, acceptable
and quality SRH services, goods, and facilities, in particu-
lar for disadvantaged and marginalised groups” (4, para
49c), including “access to comprehensive education and
information on SRH that are non-discriminatory,
unbiased, evidence-based” and that are tailored to the cap-
acities of children and adolescents (4, para 49f), and the
provision of “medicines, equipment and technologies es-
sential to SRH, including those based on the WHO Model
List of Essential Medicines” (4, para 49 g). The HPV vac-
cine is one of these recommended medicines, based on
the 2019 WHO Model List [8]. The WHO has also in-
cluded an HPV DNA testing device on its list of essential
in-vitro diagnostics for healthcare facilities with clinical la-
boratories [9]. When read together with States’ legal obli-
gations (4, para 45), these core obligations can be
understood to include non-discriminatory access to ser-
vices, information, education, medicines, and technologies
for the prevention and treatment of reproductive cancers.
Cervical cancer screening programmes should also be
aligned with the AAAQ framework: Availability, Accessi-
bility, Acceptability, and Quality of health goods and ser-
vices necessary for the right to SRH (4, paras 11–21).
Quality is of particular relevance to universal cervical
cancer control. Ensuring quality services requires provid-
ing the HPV vaccine when it is most effective at prevent-
ing disease (i.e. before first sexual activity), screening for
lesions as a scientific and medically appropriate measure
for prevention and early detection, and providing as-
sured quality cancer care in case of a cancer diagnosis.
Screening that reaches every woman
In most high-income countries, screening is standard
practice and guidelines target women most at risk of de-
veloping cervical cancer [10, 11]. By contrast, screening
is much less common in LMICs due to its high cost and
the limited health infrastructure [10, 11]. A study of six
LMICs found those with absent or newly implemented
screening guidelines had the lowest rates of crude and
effective cervical cancer screening, with high cancer inci-
dence and mortality, while countries with established
guidelines had higher screening rates and lower disease
burden [10]. Even NCSPs that are explicitly designed to
reach all eligible women may still miss the most disad-
vantaged people. NCSPs should be designed with this
challenge in mind. This requires prioritising the needs of
the most hard-to-reach women if these programmes
truly aspire to reduce health inequalities. Evidence shows
that cervical cancer-related deaths drop to ≤2 women
per 100,000 when screening (with a Pap test) is done
every 3–5 years and reaches 70% of eligible women [5,
12]. Achieving- and exceeding- this goal requires a move
towards population-based screening instead of oppor-
tunistic screening (where the latter reaches women
already in contact with the healthcare system or women
presenting symptoms of cervical abnormalities). Yet,
many women around the world go unscreened despite
the introduction of NCSPs [13].
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Indeed, social inequalities are at the heart of many
screening disparities. The examples presented below il-
lustrate commonly reported- and chronically under-
addressed- screening disparities relating to: the avail-
ability of sufficient health facilities and human resources
(Kenya); the physical accessibility of health services for
rural and remote populations (Brazil); and the accessibil-
ity of information sensitive to cultural, ethnic, and lin-
guistic barriers (Ecuador). Still, there are a number of
other, often overlapping, social disadvantages that impair
women’s universal access to screening. Structural disad-
vantages that women face include difficulty registering
with or navigating the health system, especially under-
standing one’s entitlement to care, and the cost and in-
convenience of travelling to or the screening services
themselves, among other issues [6, 14]. A woman can
face a variety of complex personal and structural barriers
that exacerbate her access to screening. Therefore, in
the context of cervical cancer screening, hard-to-reach
women are considered to be women aged 30 to 65, who
are sexually active, and who, for various reasons, are not
reached by screening services and consequently, are at
higher risk for cervical cancer [6, 14].
The availability of physicians and gynaecologists, and
an “adequate number of functioning health-care facil-
ities... to provide the population with the fullest possible
range of SRH care” (4, para 12), can be a root cause of
inaccessible screening. For example, the Kenyan Na-
tional Cancer Control Strategy 2017–2022 foresees pilot-
ing a population-based screening program in “counties
where comprehensive regional cancer centres are being
planned” [15]. Indeed, the physician-to-population ratio-
a proxy measure of the availability of trained healthcare
providers- varies significantly between different Kenyan
counties, from 1:143,000 in a hard-to-reach community
to 1:21,000 in a community with three district hospitals
[16]. Although this pilot screening program is an im-
portant (first) step, a rights-based approach will plan to
take “deliberate, targeted, and concrete” measures to
scale-up the number of health providers reaching
women beyond the areas surrounding cancer care facil-
ities (4, para 33). Ultimately, a more comprehensive ap-
proach will be needed in Kenya, where only 3.5% of
eligible women report ever being screened [13]. Conse-
quently, in Kenya- like much of sub-Saharan Africa- cer-
vical cancer is the leading cause of cancer-related deaths
among women [17].
The example of Brazil illustrates how crucial physically
accessible screening services “within safe physical and
geographic reach for all” (4, para 16) are so that women
may receive timely care, reducing the incidence of cer-
vical cancer. Brazil employs an opportunistic screening
programme that has achieved disparate levels of cover-
age and cancer survival across the country. Fragmented
screening means that women at risk or with early-stage
cancer are missed and only present to health facilities in
late stages when their chances of survival are lower [18].
In particular, ensuring women can reach health facilities
with trained gynaecologists and quality-controlled labora-
tories has limited the reach of some screening programs.
Disparate access in screening services has resulted in a de-
crease in cervical cancer-related mortality in the devel-
oped southern, southeastern, and midwestern regions of
Brazil, while an increase in the less developed areas of the
northern and northeastern regions is observed [19, 20].
Consequently, the screening benefits are not enjoyed
equally by all women in Brazil. Aware of these disparities,
some Brazilian cancer hospitals now use mobile units,
complete with laboratories, to bring screening to women
in remote locations. Between 2002 and 2012, these vehi-
cles navigated difficult terrain without roads, animal herds,
and water crossings via ferry to screen 174,605 women
who were unlikely to have otherwise been tested for cer-
vical cancer or its precursors [21].
Information and education about cervical cancer
screening, diagnosis, and preventative treatment should
be tailored and accessible to hard-to-reach women.
These measures are consistent with the ‘core obligations’
of comprehensive education and information about how
to prevent, diagnose and treat sexually-transmitted infec-
tions, such as HPV, and reproductive cancers (4, para
49f). For example, despite providing free-of-charge cer-
vical cancer screening at health facilities, Ecuador has
low national screening coverage (9–23% of eligible
women) and a high incidence of cervical cancer (19
women per 100,000) [22, 23]. In order to improve this
picture, attention should be paid to indigenous people’s
needs as they constitute 1.1 million of the 16.4 million
people in Ecuador, yet are often marginalised in health
matters [24]. Indigenous women face multiple forms of
discrimination when accessing screening provided in
health centres: language is a barrier for non-Spanish
speakers to access care and these women may experi-
ence judgement by healthcare providers [25, 26]. Indi-
vidual barriers are also at play, such as gender norms,
cultural customs, and a mistrust of Western medicine
(that are possibly related to past mistreatment), which
inhibit these women from undergoing a Pap test [26,
27]. Although these factors can have a chilling effect on
women’s screening attendance, it is most telling that in-
formation promoting screening has failed to reach indi-
genous women. Some indigenous women report first
learning about the Pap test when receiving primary care
for their first pregnancy or after their first child [27]. A
holistic public health and human rights approach re-
quires that information about sexually-transmitted infec-
tions and reproductive cancer be accessible and
“provided in a manner consistent with the needs of the
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individual and the community, taking into consideration,
for example, age, gender, language ability, education
level, disability, sexual orientation, gender identity, and
intersex status” (4, para 18–19).
Vaccination and screening
HPV vaccination is a promising strategy to prevent
high-risk infections. The HPV vaccines are extremely ef-
fective at preventing infections by common high-risk
HPV types [28, 29]. Yet HPV vaccination is most effect-
ive when given before women are exposed to the virus.
This limitation means that women who are vaccinated
before their first sexual activity will benefit most from
HPV vaccination, not women who are already sexually
active [5]. Eradicating HPV infections through vaccin-
ation is currently difficult because most immunisation
programmes only target girls and women, while boys
and men can also transmit the virus and develop HPV-
related cancers [5]. Herd immunity will be more easily
reached when all potential carriers are vaccinated. Based
on the latest demography updates, HPV vaccination pro-
vides more health benefits and is more cost-effective
than previously estimated [30].
The widescale implementation of the nonavalent vac-
cine – US Food and Drug Administration (FDA) ap-
proved in 2014 - will be another crucial step towards
stopping HPV transmission. The vaccine offers protec-
tion to 9 genotypes, of which 7 oncogenic (versus 2
high-risk HPV types in the previously approved vac-
cines), and is clinically proven to prevent HPV-related
diseases in both sexes [31].
However, HPV vaccines can only achieve these public
health gains if they are available and affordable for
women and health systems [4]. Many countries, some
with a high burden of cervical cancer, experience signifi-
cant lag time in implementing the HPV vaccine in na-
tional programmes despite its approval by the FDA over
10 years ago [32]. It is also important to remember that
HPV vaccines cannot treat pre-existing HPV infections
nor cervical cancer itself. For these reasons, the public
health benefits of recent HPV vaccinations will only be
evident in several decades [5]. In addition, vaccination
alone is unlikely to lead to cervical cancer eradication.
Therefore, vaccination should be complemented with
screening to detect treatable pre- or early-stage cancer
before it enters advanced stages [5].
Traditionally, cervical cancer screening is done by cy-
tology, where a physician, gynaecologist, or other trained
sampler (i.e. nurse or midwife) collects a sample of cer-
vical cells (commonly called a Pap test) and evaluates it
for the presence of cell abnormalities under a micro-
scope. This method was introduced in 1941 and is cred-
ited with achieving a 70% reduction in cervical cancer
rates in the USA [33]. However, processing cytological
tests is highly dependent on a sufficient number of
trained health providers to collect samples, and having
access to sophisticated laboratory equipment and highly
qualified pathologists to interpret the results. A number
of quality concerns can be triggered when laboratories
process either too few tests annually to maintain their
skills or overload technicians with too many tests, both
risking diagnostic errors [20]. Moreover, interpreting the
test is time consuming and inherently subjective, with
limited reproducibility and sensitivity to detect pre-
cancer [34]. Some women might also require a second
consultation if test results are atypical, undefined, to
conduct further testing or begin treatment.
In places unable to support high-quality cytology, vis-
ual inspection of the cervix with acetic acid, by a trained
health provider, is a low-cost and simple alternative
often recommended [5]. Indeed, alternative approaches
to cervical screening in resource-constrained settings
have been adopted including screening women once in a
lifetime using visual inspection with acetic acid (VIA) or
HPV testing, which has been found to reduce lifetime
risk of cancer by approximately 30% and cost less than
US$500 per year of life saved [35]. Visual inspection-
based screening looks for a colour change of the cervix
when acetic acid is applied. While the sensitivity of VIA
can be improved, the low specificity also leads to many
false positives and over treatment [36]. Therefore, ensur-
ing access to quality services remains a major barrier to
scaling-up universal screening programmes based on cy-
tology or visual inspection in many LMICs.
Now, new technologies to detect HPV DNA offer a
number of advantages over cytology, which can reduce
disparate access to cervical cancer screening. An HPV
test uses a sample of cells from a woman’s vagina/cervix
to detect the presence of high-risk subtypes of HPV
DNA that increase her risk of cervical cancer. It is
equally effective and a more sensitive strategy than cyto-
logical evaluation alone [37, 38]. The WHO’s 2013
Guidelines for screening and treatment of cervical can-
cer endorse HPV tests if the programme has sufficient
resources, promoting cytology only if it meets quality in-
dicators [39]. The 2015 European Guidelines for Quality
Assurance in Cervical Cancer Screening recommend the
implementation of HPV tests as a primary screening
strategy [37]. Although most HPV DNA tests still re-
quire laboratory infrastructure, some new devices make
it possible to bring the lab to the patient in a single,
handheld test (discussed further below) [40].
Modern screening methods to overcome disparities
NCSPs offering screening services and evidence-based
technologies aligned with human rights, technological
advances and modern clinical practice, and fit with the
needs of both the general population and hard-to-reach
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populations of women, have the highest potential to
achieve more [18]. Having multiple screening methods
and follow-up strategies within a NCSP to increase
coverage and continuity of care, respectively, is therefore
an alternative that more programmes should consider.
Cytology is still the most common national cervical can-
cer screening method, despite the difficulty implement-
ing them in low-resource settings (i.e. without trained
gynaecologists and pathologists, and laboratory facilities)
[41]. In this regard, HPV DNA testing offers several ad-
vantages over cytology for expanding screening with lim-
ited resources to hard-to-reach populations.
First, HPV DNA testing allows women to take self-
samples (i.e. to collect cells from herself using a vaginal
swab), which is not compatible with cytology. Self-
sampling is associated with higher screening coverage,
particularly among vulnerable populations facing linguis-
tic, cultural, geographic, or economic barriers [42–44]. It
is also highly accepted by women because it is more
discrete and less invasive than physician-obtained sam-
ples [45]. Furthermore, self-sampling “has the potential
to further empower women to collect their own samples
in privacy giving them control over how and when they
participate in screening” [46]. HPV test results obtained
in self-sampled material are highly concordant with
those obtained by physicians [47–51]. Self-sampling is a
strategy to increase screening participation, particularly
among hard-to-reach women, because it can be safely
and effectively done with support from community
health workers (instead of physicians or gynaecologists)
or by women alone [48, 52].
Second, screening by self-sampling in populations of
hard-to-reach women can be further enhanced if used
together with a user-friendly HPV rapid testing device.
One of the remaining limitations of HPV testing is its
reliance on laboratory infrastructure to process the re-
sults. However, HPV rapid testing devices can alleviate
this constraint by bringing a portable molecular DNA
test to women. Some of the present authors are part of
the international research consortium, ELEVATE, which
recently launched a five-year project financed by the
European Commission’s Horizon 2020 programme to
develop a new test and screening approach for cervical
cancer in hard-to-reach women. The test will combine
self-sampling with a new low-cost, portable measure-
ment device that will be validated in screening trials in
Belgium, Brazil, Ecuador, and Portugal. The new ELEV
ATE HPV test will yield easy-to-understand results in
low-resource settings lacking specialist health personnel
or electricity in remote locations. Point-of-care results
mean that women can be screened and receive their re-
sults in the same visit, resulting in increased continuity
of care and efficient follow-up processes. How such a
device can be an added value to under-screened women
is highly context dependent (i.e. home-based self-
sampling, community mobilisation for testing, testing
followed by clinician counselling, or in other combina-
tions) [53]. Therefore, the ELEVATE project will also
execute pilot studies in hard-to-reach populations to de-
termine the feasibility, user and health provider accept-
ability, costs, logistics, and population compliance of
self-sampling and the rapid HPV testing device [54, 55].
The budget impact of the HPV test has been a barrier to
its widespread introduction in some LMICs. Nevertheless,
NCSPs should consider a self-sampling and HPV testing
method to reach under-screened women, remembering
that governments may need to devote “greater resources
to [these] traditionally neglected groups” to eliminate sys-
temic discrimination and ensure their right to SRH (4,
para 31). The cost-effectiveness of HPV testing methods
has been shown in various contexts, while maintaining or
even improving effectiveness compared to traditional cy-
tology programmes [56]. Studies on primary HPV testing,
including self-sampling methods, followed by triage for
HPV-positive cases are also shown to be cost-efficient and
effective in Brazil [57]. In Canada, for example, self-testing
in rural populations, when combined with community en-
gagement and education, is effective at increasing cover-
age in underserved populations and is a cost effective
alternative [52].
Conclusion
The crux of cervical cancer control rests in prevention
through vaccination and early detection through screen-
ing. Until now, many NCSPs have been unresponsive to
important social inequalities that marginalise some
groups of women, hampering universal access to screen-
ing services. Under-screened women have a higher bur-
den of cervical cancer and worse survival rates than
regularly-screened women. Yet, there is good reason for
Dr. Tedros to call cervical cancer “a NCD we can over-
come” [2]. Governments have human rights obligations
to refocus screening policies and programmes on
women who are disproportionately affected by discrim-
ination that impairs their full enjoyment of the right to
SRH (4, paras 30–31). To reach underserved women,
NCSPs also rely on and can contribute to strengthening
the six building blocks of health systems: (1) innovative
approaches to health services, such as screening through
mobile health units and community health workers; (2)
health information systems to manage immunisation
and screening records, and community outreach in a
language and manner that is acceptable to the target
population; (3) an adequate number of trained health-
care providers to immunise, screen/sample, and inter-
pret test results; (4) regular supply of self- sampling and
point-of-care HPV testing devices that are acceptable to
marginalised women and health providers, and of HPV
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vaccines (from a temperature-assured supply chain) that
are available at an affordable price; (5) adequate finan-
cing for the foregoing measures; and (6) leadership and
good governance to implement these measures through
out the health system with particular attention for hard-
to-reach populations [58]. NCSPs should tailor screening
methods to under-screened women, bearing in mind
that eliminating systemic discrimination may require
“devoting greater resources to traditionally neglected
groups” (4, para 31). NCSPs that keep these human
rights principles central will be able to expand screening
among low-income, isolated and other marginalised
populations, but also women in general, who, for a var-
iety of reasons, do not visit healthcare providers for
regular screenings. With so much political will and glo-
bal momentum towards eliminating cervical cancer as
part of NCD control, the time is right to invest in
evidence-driven, rights-based, innovative screening prac-
tices that target underserved women globally.
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